This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
We reached out to our incredible Healthcare IT Today Community to get their insights on what will happen in the coming year and boy did they deliver. Drug discovery and development will see the most dramatic impact, with AI-powered processes reducing development timelines from 10-12 years to as little as a quarter of that time.
Welcome to our Healthcare IT Today Weekly Roundup. Each week, well be providing a look back at the articles we posted and why theyre important to the healthcare IT community. We have plenty more predictions from the Healthcare IT Today community. No hard feelings if you did – I was off for a few days, too.) Happy 2025!
Drug population and drug protocol fit account for nearly 75% of these failures. By simulating trials at scale, QuantHealth’s platform can lower risks, expedite, and optimize drugdevelopment. Petra Jantzer, Ph.D.,
In our interview, Gil emphasizes the critical role of AI in expediting the discovery of new drugs, citing the lengthy and costly nature of traditional drugdevelopment processes. However, with AI-driven approaches, Aion Labs is paving the way for a paradigm shift in drug discovery. Tell us what you think.
The companies drew particular attention to Labcorp DrugDevelopment, which Ascension says it can use to present physicians and patients with access to clinical trials, innovative therapies and new treatment options where appropriate. Kat Jercich is senior editor of Healthcare IT News. Twitter: @kjercich. Enterprise Taxonomy:
This is the pathway toward achieving human digital twins, dynamic models that not only reflect and allow health monitoring but also enhance patient stratification, improve the success rates of drugdevelopment programs, and enable treatment testing before application.
Artificial intelligence (AI) holds great promise to dramatically improve clinical outcomes for patients, but in a perverse twist, AI algorithms that are used to improve drugdevelopment and support healthcare don’t just highlight social inequities — they may ultimately exacerbate them. A lingering […].
The companies are evolving in many ways, including stepping outside drugdevelopment to tryout digital treatments and using lessons from the COVID-19 pandemic to rethink production and clinical trials. Where are pharma companies investing their windfall profits?
In this video, he describes other ways that AI can make drugdevelopment more efficient. At the design stage, a drug company can run millions of simulations to determine where risks lie and what parameters are most promising. Pryluk also discusses equity and explainability. Watch the video for more insights.
We reached out to our incredible Healthcare IT Today Community to get their insights on what will happen in the coming year and boy did they deliver. Connor Landgraf, Co-Founder and CEO at Eko Health 2025 is the year when the rubber meets the road in AI technologies in healthcare. We could not do this without all of your support.
Curebase today announced $15M in Series A funding to continue developing its decentralized clinical trial software platform and virtual research site capabilities, powering research where any patient, anywhere, can be part of clinical trials at home and with their own doctor.
He also said that the benefits go beyond doctors; for instance, care coordinators can be more efficient and AI can help drugdevelopment. Learn more about UST: [link] Listen and subscribe to the Healthcare IT Today Interviews Podcast to hear all the latest insights from experts in healthcare IT. Tell us what you think.
That doesn’t just lead to faster trials, it changes the way companies can think about drugdevelopment going from waterfall big bets to agile research.” . “We’re fixing that with a new paradigm for running trials underpinned by technology.
As precision medicine becomes more nuanced and complex, biopharmaceutical companies are increasingly turning to AI to enhance the utility, performance, and scalability of computational pathology analyses for drugdevelopment and diagnostics.
The COVID-19 pandemic has presented an opportunity for non-contact patient monitoring technologies, which can facilitate the early detection of respiratory complications in suspected patients, while reducing the chances of infection among physicians and healthcare workers. THE LARGER CONTEXT.
Here they are producing more accurate and efficient tools for drugdevelopment. The biotherapeutics monitoring equipment from 908 Devices illustrates the positive role technology—sensitive measuring devices, analytics, and automation—can play in medicine.
In case you need some help starting this goal, we reached out to our incredible Healthcare IT Today Community to ask how can healthcare organizations address social determinants of health (SDoH) to reduce disparities and promote health equity in underserved communities?
We asked the Healthcare IT Today community to submit their predictions and we received a wide ranging set of responses that we grouped into a number of themes. Discussions will focus on the nuanced packaging and delivery requirements for MABs, emphasizing the commitment to safety standards while ensuring the drugs’ effectiveness.
Visit www.nelsonadvisors.co.uk #HealthTech #DigitalHealth #HealthIT #NelsonAdvisors #Mergers #Acquisitions #Growth #Strategy Background to HLTH 2024 HLTH is a leading healthcare conference that brings together industry leaders, innovators, investors, and entrepreneurs to discuss the future of healthcare.
Welcome to our Healthcare IT Today Weekly Roundup. Each week, we’ll be providing a look back at the articles we posted and why they’re important to the healthcare IT community. In this video, R-Zero Systems CEO and Co-Founder Grant Morgan explores use cases for UV technology in healthcare for COVID and beyond.
New healthcare AI and Machine Learning research conducted by Healthcare IT Today suggests that many industry leaders are serious about adopting healthcare AI and machine learning tools and what’s more, that these technologies are being used as part of mission-critical efforts rather than one-off pilot tests.
He sees three major developments: healthcare will become a digital-first system; decentralization will become a major theme for health and life sciences organizations; and video will be part of every healthcare experience. Healthcare IT News interviewed Emerson to have him expand upon his predictions for the year.
This ML-driven adaptive process can significantly accelerate the clinical drugdevelopment process and increase certainty along the way, resulting in more efficient, targeted, and ultimately more successful clinical trials.
The company will use this new funding to further expand its real-world data platform and services in order to drive more efficient and inclusive drugdevelopment in oncology. In conjunction, COTA announced it has raised additional capital from existing investors. COTA Adds Emerging Types of Data to Oncology Real-World Data Platform.
Cofounded by Dr. Siddhartha Mukherjee and Reid Hoffman, Manas AI Leverages Proprietary AI, Generative Computational Chemistry, and Best-in-Class Biology to Cut DrugDevelopment Timelines and Costs, Transforming Cancer and Rare Disease Treatments Company Raises $24.6
About AllStripes Founded in 2017, AllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare diseases. Originally announced October 23rd, 2023
We’re already seeing the benefits of AI-infused research in pharmaceuticals and drugdevelopment. According to WEF , the largest ten pharmaceutical companies have either partnered with or acquired AI companies to make use of AI-assisted drugdevelopment and design.
“We are excited to announce this funding that supports our mission to enhance the drugdevelopment pathway from discovery through commercialization,” said Eran Seger, Co-Founder and CEO at Protai. “I We look forward to scaling our organization and its important work towards revolutionizing the drugdevelopment landscape.” “Our
Welcome to the inaugural edition of Healthcare IT Today Bonus Features. Because there’s so much happening out there in healthcare IT we aren’t able to cover in our full articles, we still want to make sure you’re informed of all the latest news, announcements, and stories happening to help you better do your job. .”
Welcome to the weekly edition of Healthcare IT Today Bonus Features. Because there’s so much happening out there in healthcare IT we aren’t able to cover in our full articles, we still want to make sure you’re informed of all the latest news, announcements, and stories happening to help you better do your job.
.” “The massive proliferation of patient data, coupled with advances in analytical methods, can enable providers and pharmaceutical companies to transform clinical decision-making, optimize drugdevelopment, and ultimately improve patient outcomes,” said Tyler Schinto from Presidio Ventures.
.” Prognos Health’s platform is used by over 70 life sciences customers to accelerate the development of new drugs, improve the safety and efficacy of existing drugs, and identify new patient populations that may benefit from specific treatments.
Redi.Health recently forged partnerships with several healthcare heavyweights like GoodRx and ScriptDrop, as well as a collaboration with Labcorp that integrates the Labcorp DrugDevelopment Patient Access Solutions with Redi.Health’s digital support platform to more seamlessly connect patients and providers. .
Blockchain technology’s potential impact on the life sciences industry (drugdevelopment, distribution and prescribing) is significant. It can impact the opioid crisis and improve tracking drugs in the supply chain. One can envision how blockchain might also stop drug counterfeiting thereby improving patient safety.
Several key trends and predictions are emerging: Increased focus on digital health and AI: AI-powered diagnostics and drug discovery: Companies specialising in AI-driven medical imaging, genomics analysis, and drugdevelopment are likely to attract significant interest from larger pharmaceutical and technology firms.
We are particularly excited about the ability of these tools to drive more efficient and faster drugdevelopment processes in the biopharma industry.” “The “We believe Flywheel’s unique software solutions enable the smarter use and interpretation of the vast amounts of information associated with large numbers of medical imaging scans.
“Data quality has become one of the biggest problems in the healthcare industry – one that has significant consequences,” said Cornerstone Co-founder and CEO Michael Elashoff. Poor quality data leads to drugdevelopment being delayed, patients being misdiagnosed and inaccurate scientific conclusions.
To help healthcare CIOs, CMOs and other leaders find connected health devices and RPM technologies, Healthcare IT News has compiled this comprehensive listing of vendors. Healthcare IT News is a HIMSS Media publication. Hospitals across the nation are using connected health and RPM to great effect during the pandemic.
It will become part of Fujifilm’s Synapse Enterprise Imaging portfolio – an award-winning suite of healthcare IT solutions that unify imaging, data access and workflows across the health system. According to a recent DeciBio article, Dynamyx is shown to have one of the largest partnership networks in the digital pathology space.
Within Life Sciences, the firm focuses on MedTech, Diagnostics, and Opportunistic DrugDevelopment. With Partners in Nashville, TN and Atlanta, GA, SeedToB Capital invests in early-stage businesses driving adoption of innovative technology within the healthcare ecosystem. For more information, visit www.mtngp.com.
Exec Summary: Generative AI is a powerful new tool with the potential to revolutionize healthcare. It can be used to create new drugs, develop personalized treatment plans, and even generate synthetic medical data. But how can healthcare organisations best leverage this technology?
“Virtual care has a significant role to play in the future sustainability of healthcare systems around the world,” observes Kate Kelly, Managing Director UK & Ireland, Inizio Engage, a global strategic, commercial and creative engagement agency specialising in healthcare. “It
Healthtech is a broad term that encompasses the use of technology to improve healthcare. Drug discovery: AI-powered tools will accelerate the drugdevelopment process by analyzing vast datasets. smart phone apps, pregnancy testing) to complex robotic surgical systems used by specialist clinicians.
Already, this real-world, distributed time of diagnosis approach, has been used to cut down more than four years of estimated drugdevelopment timeline in the instance of PRAX-222, a new therapy for SCN2A, a rare genetic disorder of pediatric epilepsy.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content